ERCC1 and nasopharyngeal carcinoma: Xu et al. reported respective CCRT response rates of 76.9% and 56.6% for ERCC1− and ERCC1+ patients with regionally moderate advanced nasopharyngeal carcinomas [14,15], and Jun et al. reported a significantly higher three-year overall survival rate in patients with low ERCC1 expression (91.7; 95% CI, 76.0–100.0%) compared with high ERCC1 expression patients (45.5; 95% CI, 23.9–67.1%; p = 0.013).